Key facts
- JSIAMA Biopharmaceuticals’s last known valuation is $66.2M (Mar 2025).
- It has raised $6.9M; the latest was Early Stage VC ($6.9M) in Mar 2025.
- Notable investors include Tailong VC, Prosperico Ventures, Zhejiang Hisun Pharmaceutical Company.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for JSIAMA Biopharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for JSIAMA Biopharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About JSIAMA Biopharmaceuticals
Developer of clinical-stage biopharmaceuticals designed for innovative immunotherapies targeting respiratory diseases, including cancer. The company focuses on the discovery and development of novel drug platforms, providing healthcare professionals with therapeutic solutions for conditions like allergic rhinitis, allergic dermatitis, respiratory infections, and vaccine adjuvants.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2021
- Website
- iamabio.com/
- Ownership
- Privately Held (backing)
JSIAMA Biopharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in JSIAMA Biopharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on JSIAMA Biopharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.